Table 6.
Intravenous golimumab effectiveness by clinical scale
| CDAI, n = 22 | PhGA, n = 25 | PtGA, n = 39 | RAPID3, n = 28 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-GLM | Post-GLM | p valuea | Pre-GLM | Post-GLM | p valuea | Pre-GLM | Post-GLM | p valuea | Pre-GLM | Post-GLM | p valuea | |
| Total mean score | 21.6 ± 12.3 | 8.5 ± 8.1 | < 0.001 | 5.1 ± 2.0 | 2 ± 1.9 | < 0.001 | 5.8 ± 2.3 | 4.2 ± 2.6 | 0.002 | 14 ± 5.3 | 13.9 ± 5.7 | 0.913 |
| 2-level classification | ||||||||||||
| Remission/low | 4 (18.2) | 15 (68.2) | 0.003 | 1 (4.0) | 13 (52.0) | 0.002 | 4 (10.3) | 10 (25.6) | 0.146 | 2 (7.1) | 3 (10.7) | 1 |
| Moderate/high | 18 (81.8) | 7 (31.8) | 24 (96.0) | 12 (48.0) | 35 (89.7) | 29 (74.4) | 26 (92.9) | 25 (89.3) | ||||
| 4-level classification | ||||||||||||
| Remission | 1 (4.5) | 6 (27.3) | < 0.001 | NA | NA | 2 (7.1) | 2 (7.1) | 0.48 | ||||
| Low | 3 (13.6) | 9 (40.9) | 0 (0.0) | 1 (3.6) | ||||||||
| Moderate | 10 (45.5) | 5 (22.7) | 7 (25.0) | 7 (25.0) | ||||||||
| High | 8 (36.4) | 2 (9.1) | 19 (67.9) | 18 (64.3) | ||||||||
Data are presented as mean ± standard deviation or f (%)
CDAI Clinical Disease Assessment, GLM golimumab, PhGA Physician Global Assessment, PtGA Patient Global Assessment
aStatistically significant differences between pre- and post-GLM on the clinical classification were assessed via McNemar χ2 test; differences in means were assessed via paired t tests